Self-Assembled Hybrid Nanostructures: Versatile Multifunctional

Subscriber access provided by READING UNIV

Review

Self-Assembled Hybrid Nanostructures: Versatile Multifunctional Nanoplatforms for Cancer Diagnosis and Therapy Menghuan Li, Zhong Luo, and Yanli Zhao Chem. Mater., Just Accepted Manuscript • DOI: 10.1021/acs.chemmater.7b03924 • Publication Date (Web): 17 Nov 2017 Downloaded from http://pubs.acs.org on November 18, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Chemistry of Materials is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Chemistry of Materials

Self-Assembled

Hybrid

Nanostructures:

Versatile

Multifunctional

Nanoplatforms for Cancer Diagnosis and Therapy Menghuan Li,†,‡ Zhong Luo*,† and Yanli Zhao*,‡,§ †

School of Life Science, Chongqing University, Shapingba District, Chongqing, 401331 P.R.

China. E-mail: [email protected] ‡

Division of Chemistry and Biological Chemistry, School of Physical and Mathematical

Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371, Singapore. E-mail: [email protected]. §

School of Materials Science and Engineering, Nanyang Technological University, Singapore

639798, Singapore

Abstract: Self-assembled organic-inorganic hybrids are a class of promising nanomaterials possessing interesting physiochemical and biological characteristics, making them highly attractive in cancer-related biomedical applications. By using self-assembly as a synthetic tool and various organic/inorganic species as the building blocks, scientists are able to create a myriad of hybrid nanosystems. These promising nanosystems show favorable nano-bio interfacial properties, while still retaining their physical/chemical functionalities. The present review aims to provide a systematical overview of the self-assembled hybrid nanostructures and highlight their implementations in cancer diagnosis and treatment by reference to notable recent examples. In addition, the existing challenges in the bench-to-bedside translation of these nanotherapeutics as well as the potential technological breakthroughs in the future studies were also discussed in detail. Overall, this review presents how clinical oncology could benefit from the convergence of self-assembly paradigm and nanotechnology.

Keywords: anticancer therapy, clinical translation, diagnostics, hybrid nanomaterials, selfassembly

1 Environment ACS Paragon Plus


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1. Introduction The expansion of nanotechnology has provided new avenues for the prevention,1, 2 diagnosis3, 4

and treatment5 of a variety of cancers, as the performance of conventional pharmaceuticals

are severely limited by their intrinsic physio-chemical properties.6, 7 Thanks to their small sizes (from 10 nm to a few hundred nanometers) and tunable characteristics, pharmaceutical nanoagents hold great promise in addressing the health problems associated with cancer.6 Pharmaceutical nanostructures could be synthesized from a variety of raw materials, such as lipids,8,

9

polymers,10 nucleic acids,11 proteins12 and many other inorganic materials.13

Additionally, the biological activities of these nanostructures could be tailored and improved by surface engineering,14, 15 which may further expand their potential use in pharmaceutical applications. These intriguing properties have inspired numerous concepts and designs for advanced biomedical nanosystems. In particular, those nanostructured biomaterials fabricated through the self-assembly of organic/inorganic hybrid building blocks have demonstrated a myriad of powerful advantages in laboratory and preclinical studies, which may lead to promising applications for cancer-related diagnosis and treatment. Self-assembly is usually described as an energy minimization process that generates a large well-defined structure by the spontaneous repetition of smaller ones, which is determined by the size, amount/geometry of the structural unit and the strength of interactions among the units. Different from the covalent conjugation strategies, the self-assembly approach relies on those relatively weaker noncovalent forces such as hydrogen bonding interaction, electrostatic association, van der Waals interactions, and hydrophobic interaction to organize the building blocks into well-defined spatial configurations.16 Within this perspective, using the self-assembly for the construction of organic/inorganic hybrid nanobiomaterials could not only combine the intrinsic properties of the heterogeneous building blocks, but also potentially attain new physical, chemical and biological functions through the supramolecular interaction among them. Based on our own research as well as other critical studies, we review the scientific progress in organic/inorganic hybrid nanomaterials that are either formed by self-assembly or require self-assembly events to achieve certain functions (Scheme 1), as well as the balancing between their functional novelty and clinical relevance. This review starts with a brief discussion on the cancer-related applications of self-assembly nanotechnologies and inorganic preparations to justify the interest in the development of self-assembled hybrid nanobiomaterials. Subsequently, we provide a comprehensive compilation of recent representative studies in this field, which is organized depending on the proposed clinical applications and then the inorganic components 2 Environment ACS Paragon Plus

Page 2 of 64

Page 3 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


involved. We focus on the integration of self-assembly technology for the development of hybrid nanobiomaterials, which should possess the desired nano-bio interface properties similar to those self-assembled organic nanoplatforms, while retaining the unique functionality of the inorganic components. At the end of this review, we highlight their potential clinical advantages and existing challenges, with the objective to increase the scientific and technological investment in this field.

Scheme 1. A schematic illustration of the review content.

2. General considerations on nanotechnology-enabled cancer diagnosis and therapy In the past few decades, there has been a surge of using nanotechnology for oncological applications. However,

only a

small number of theranostic nanosystems reach

commercialization stage. Nevertheless, both the successes and failures of these trials may provide insights into the preparation and utilization of nanomaterials from a more balanced perspective, which could be indicative for the future development of nanomaterials in the cancer diagnosis and therapy. Although there are still no internationally accepted regulations



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

currently available for the development and administration of nanosystems in oncology, a number of criteria have been proposed and commonly used by material scientists and clinicians, which may facilitate the bench-to-bed translations of nanosystems for cancer diagnosis and treatment. 2.1 Design rationales of nanosystems for cancer therapy Long circulation half-life. When administered intravenously, the drug-loaded nanocarriers have to avoid various clearance mechanisms in order for the drug to reach the tumor tissues. Therefore, some design features of the nanocarriers have to be tailored to prolong their blood circulation time. Typically, nanoparticles with a size less than 5 nm are rapidly removed from the blood through extravasation and renal clearance, while those sized around several hundred nanometers tend to accumulate in liver, spleen and bone marrow. Consequently, the nanocarriers should be larger than the renal filtration threshold, but small enough to avoid the non-discriminating uptake by liver and spleen. Moreover, nanocarriers without an appropriate surface modification could quickly bind to the serum proteins and are subsequently removed by the macrophage phagocytic system (MPS). A common approach to solve this issue is to conjugate hydrophilic polymers (exemplified by poly(ethylene glycol), i.e., PEG) onto the surface of the nanocarriers, which could form a hydrated barrier to reduce opsonin adsorption. Tumor specificity: EPR effect and active targeting. There are two basic approaches to enhance the selectivity and specificity of the drug delivery, which are realized through passive accumulation (passive targeting) and tumor-targeting vectors (active targeting). For the passive targeting approach, it is well known that tumor blood vessels are usually highly abnormal, and the vessel walls are more “leaky” than normal vessels. As a result of the fenestrated tumor vasculature and damaged lymphatic drainage combined, nanoscale substances could leak from the tumor microvessels and accumulate in the tumor parenchyma. This phenomenon is formally named as the enhanced retention and permeability (EPR) effect. The actual efficiency of EPR-dependent drug delivery could be affected by a number of factors, including size, charge and surface chemistry. For instance, previous reports indicate that nanoparticles should be in the size range of 50-150 nm so as to extravasate from the neovasculature, while the surface modification of hydrophilic polymers like PEG could significantly prolong the blood-circulation half-life of nanomaterials and thus improve their accumulation at the tumor site.17 Active targeting is another approach that may potentially enhance the nanoparticle accumulation at the tumors while minimizing the collateral damage, which improves the EPRenabled targeting effect through the conjugation of tumor-specific ligands. These ligands are 4 Environment ACS Paragon Plus

Page 4 of 64

Page 5 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


designed to bind to their target receptors that are overexpressed in tumor cells. In an ideal circumstance, the ligand-receptor interaction could trigger efficient and specific internalization of the nanoparticles. Currently, some of the most exploited tumor-specific targets are folic acid receptors, transferrin receptors and integrin receptors. As our understanding of the tumor biology deepens, a variety of new targeting ligands are already underway, which may present unique advantages for the treatment of various tumor indications.10, 18 Barrier penetration and drug release control. The complexity of tumor tissues has created a series of biological barriers that impede the therapeutic action of drug-loaded nanocarriers, which include cancer associated fibroblasts, acidic pH, hypoxia, high interestitial pressure, etc. These obstacles are sufficient to confer resistance to existing treatment modalities. Therefore, nanocarriers should also be able to overcome these barriers to enhance the efficacy against the targeted tumors. For instance, Zhou et al conjugated recombinant human hyaluronidase PH20 onto the surface of nanocarriers to enhance the drug penetration in tumors, which could degrade the tumor extracellular matrix to facilitate interstitial diffusion.19 Alternatively, scientists have proposed and evaluated a number of strategies that may potentially overcome the aforementioned mechanisms of treatment resistance, such as nanocarriers that may undergo a size reduction20 or charge reversal21 process in response to certain triggers in the tumor microenvironment. Nevertheless, it should also be mentioned that complex tumor microenvironment may also create opportunities for tumor therapy with nanomaterials. By taking advantage of the difference between tumor and normal tissues, nanocarriers could also be fabricated in such a way that the drug release could be initiated in the tumor microenvironment by a certain triggering mechanism. These stimuli could be endogenous (pH, redox potential, reactive oxygen species level, etc) or exogenous (light, hyperthermia, magnetic field, ultrasound, etc). Compared with those non-responsive nanosystems from which the encapsulated drugs are released through uncontrollable random diffusion, these stimuli-responsive nanocarriers allow the tailoring of the release profiles to adapt specific needs of patients. Safety. Safety has always been the major factor of consideration for the development of nanomedicine. Materials with dimensions at the nanoscale could provide many desirable attributes for biomedical applications, yet they are also inevitably associated with some other adverse biological activities that may present hazards to the patients. Therefore, nanomedicine must be made from compounds of biological origin, or at least bio-inert substances, therefore ensuring their non-toxicity and immunocompatibility. Moreover, the nanocarriers should be 5 Environment ACS Paragon Plus


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

able to self-degrade in vivo or be cleared from the body to minimize the risk of long-term health problems. Additionally, as properties of nanomaterials may vary significantly even within the same class, their efficacy and safety are required to be evaluated on a case-by-case basis.

2.2 Design rationales of nanosystems for cancer diagnosis The introduction of nanotechnology has offered a new promise for early and accurate detection of cancer, which is of equal importance to medical treatment. It is well known that certain materials may provide unique chemical and physical properties when their size is reduced to the nanoscale, which could be potentially used as diagnostic agents with better performance. The technical and regulatory considerations associated with these diagnostic nanosystems are briefly summarized below. Improving the signal-to-background ratio. To detect the evidence of malignancy in a sample, the signal generated by contrast mechanisms at the tumor must be stronger than the background noise. Therefore, to enhance the clinical efficiency of a diagnostic probe, one may choose to enhance the signal that corresponds to the tumor or lower the background, or both at the same time. For instance, Mi et al reported a pH-activatable Mn2+-doped calcium phosphate nanoparticle capable of amplifying magnetic resonance signals in the acidic tumor environment, which could be used to detect invisible millimeter-sized metastatic tumors in the liver.22 Tumor sensitivity, resolution and specificity. Early diagnosis is particularly important for patients with many cancer indications, and its realization essentially requires new diagnostic modalities with higher sensitivity and better resolution. Enhancing the resolution and sensitivity of cancer diagnosis may facilitate clinicians to detect even smaller cancers and more accurately predict the therapeutic responses, which is crucial to improve survival rates. Moreover, it was reported that the nanoprobes could also be with tumor-targeting ligands to achieve highly specific imaging of the tumor site,23 which may facilitate the molecular characterization of the tumor tissue. Functionality and safety. From an overall perspective, the safety criteria of diagnostic nanosystems for in vivo applications are similar to those of the drug nanocarriers, such as the requirement of clearance ability, non-toxicity and immunocompatibility. Nevertheless, some properties like effective size and surface functionalization may vary depending on the diagnostic modalities and specific functions. For instance, some nanoparticle imaging probes were designed to be long circulating, which potentiate the repetitive imaging of the tumor area 6 Environment ACS Paragon Plus

Page 6 of 64

Page 7 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


without the need of additional administration of imaging probes. In some circumstances, however, the probes should be able to be rapidly eliminated to avoid unspecific retention, which may result in increasing background noise and long-term health risks.24 These issues highlight the importance of balance between functions and safety for diagnostic nanoprobes, which again suggest the necessity that the safety and performance of these nanosystems should be analyzed and optimized on an individual basis.

3. Self-assembled organic nanosystems for cancer-related applications Currently, a series of self-assembly-based organic imaging and/or therapeutic agents for cancer diagnosis and treatment have been successfully commercialized or entered clinical trial stage.25, 26 For instance, liposomes, which are essentially spherical vesicles consisting of fluid enclosed by one or more self-assembled bilayers of natural or synthetic phospholipids, are one of the most successful self-assembled biomedical nanoplatforms since the emergence of nanomedicine. They have been found broad application in cosmetic, pharmacy, food and agriculture industry and approved for cancer therapy in 1995. It has so far demonstrated great application potential.27, 28 In the study by Spring et al, they developed a photo-responsive multi-inhibitor liposome that is capable of synchronous light-induced chemotherapy and inhibition of treatment resistance, which offers novel prospects for the realization of spatiotemporally controlled drug release and reduced ill effects.29 Compared with those conventional administration approaches, these delivery systems could provide many pharmacologically favorable properties such as the entrapment of water-insoluble drugs, manipulation of pharmacokinetic parameters, alleviation of side effects and enhanced resistance to physiological degradation of bioactive agents, thus significantly improving the pharmacological efficacy while minimally impacting healthy tissues and organs. The manufacturing approaches and clinical advantages of these self-assembly-based nanosystems have been thoroughly and excellently discussed in several recent reviews.30-32 Tables 1 and 2 list some representative self-assembled organic nanosystems for cancer diagnosis and treatment in clinical practice and clinical trials.33-54

Table 1. Some self-assembled organic nanosystems that are currently used in clinical practice. Platform type

Trade name

Formulation

Indication

Clinical benefit

Ref.

Liposomes

DaunoXome

Liposomal daunorubicin

Breast cancer, advanced HIV-

Enhanced drug deposition in

associated Kaposi sarcoma, acute

tumor, decreased side effects,

nonlymphocytic leukemia, ovarian

also capable of escaping multi-


33


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 8 of 64

cancer, multiple myeloma

drug resistance

Used together with Myocet

Liposomal doxorubicin

cyclophosphamide for the first-line

Decreased cardiotoxicity and

treatment of metastatic breast

enhanced in vivo retention

34

cancer in adult women Doxil/Caely

PEGylated liposomal

x

doxorubicin

Marqibo

Liposomal vincristine

Mepact

Liposomal mifamurtide Liposomal eribulin

Halaven

mesylate

HIV-associated kaposi sarcoma,

Increased circulation stability

ovarian cancer, breast cancer,

35

and reduced cardiotoxicity

multiple myeloma Leukemia, Hodgkin disease, non-

Long

Hodgkin lymphomas, Wilms'

enhanced tumor accumulation,

tumor, rhabdomyosarcoma,

sustained drug release and

neuroblastoma

reduced neurotoxicity

Osteosarcoma

Longer plasma half-life

Breast cancer, liposarcoma

circulation

Relatively

wide

window

and

half-life, 36

37

therapeutic favorable

38

pharmacokinetics

Micelles

Genexol-PM

PEGylated micellar paclitaxel

Permitting much higher doses

Breast cancer, small cell lung

to be used and enhanced tumor

cancer

39

distribution

Supramolecular protein-drug formulation

Abraxane

Albumin-bound paclitaxel

Breast cancer, pancreatic cancer,

Reduced

non-small-cell lung cancer

circulation time

toxicity,

increased

40

Table 2. Some self-assembled organic nanosystems currently in clinical trials. Name

MM-302®

Thermodox®

Promitil®

Sponsor

Merrimack

Celsion

Lipomedix Pharmaceuticals

Composition

Indication

HER2-targeted antibody–

HER2-positive

liposomal doxorubicin

advanced/metastatic

conjugate

breast cancer

Celator

CPX-351

Pharmaceuticals

tolerance and superior antitumor

Primary liver cancer

in thermosensitive

/ recurrent chest

efficiency (25 fold)

liposomes

wall breast cancer

release

in PEGylated liposomes

Solid Tumor and metastatic colorectal cancer

daunorubicin (molar ratio 5:1) encapsulated in

trial phase

Ref.

II

41

(Stopped)

activity

Doxorubicin encapsulated

Mitomycin-C encapsulated

Clinical

Better in vivo

Enhanced delivery

Cytarabine and Vyxeos® /

Advantage

and triggered drug

III

42

I

43

III

44

II

45

Significantly improved toxicity profile than free mitomycin-C Superior response

Leukemias

rate and no increase in serious toxicity

liposomes

Improved Oncoprex

Genprex

TUSC2 gene encapsulated

Non-small cell lung

antitumoral efficacy

in cationic liposomes

cancer

with minimal side effects


Page 9 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Mitoxantrone

CSPC ZhongQi

Mitoxantrone HCL

hydrochloride

Pharmaceutical

(Novantrone) entrapped in

liposome

Technology

Malignant

Improved safety

lymphoma

profile and efficacy

Plasmid DNA complexed

Acute myelogenous

Inducing significant

with cationic liposomes

leukemia

innate immunity

liposomes

I

46

I

47

I

48

III

49

I

50

I

51

III

52

I

53

II

54

Juvaris BioJVRS-100

Therapeutics Inc.

Lipocurc

SignPath Pharma, Inc.

Curcumin encapsulated in liposomes

Enhanced delivery Solid tumors

reduced side effects

Cisplatium incorporated in LiPlaCis

LiPlasome

liposomes, can be degraded

Metastatic breast

Pharma

by secretory phospholipase

cancer

A2 (sPLA2)

AZD2811

AstraZeneca, Pfizer

Selective uptake of formulated drug at the tumor site Enhanced

Aurora kinase inhibitor incorporated in polymeric

efficiency and

Solid tumors

micelles via ion pairing

therapeutic index and preclinical efficacy Controlled drug

CriPec

Cristal Therapeutics

Docetaxel entrapped in micelles

release at the tumor Solid tumors

site, improved efficacy and tolerability

NK105

Nippon Kayaku Co., Ltd.

Paclitaxel-incorporating micelles

Superior activity and Breast cancer

paclitaxel

Diaminocyclohexane NC-4016

NanoCarrier Co., Ltd.

platinum entrapped in

Advanced solid

micelles via polymer-metal

tumors, lymphoma

complexation

CRLX101

Cerulean Pharma Inc.

Camptothecin complexed to a linear, cyclodextrinbased polymer

tolerability of

Increased cell permeability and enhanced retention Long circulation

Advanced solid

half-life and

tumors

sustained drug release

As demonstrated in these tables, both synthetic and natural organic species (including their functional derivatives) could be used for the fabrication of self-assembled nanomedicine. The major advantage of synthetic organic building blocks is that they could be prepared with high cost effectiveness and purity while exhibiting tailor-made biological properties. For example, PEG, polylactide (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL), poly(butylene succinate) (PBS) and poly(p-dioxanone) (PPDO) are frequently used synthetic constituents for the fabrication of self-assembled nanobiomaterials, all of which have been approved by FDA for certain in vivo biomedical applications.55 Specifically, due to the minimal immunogenicity /antigenicity/toxicity and



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 64

high hydrophilicity, PEG has been widely employed in various self-assembled nanosystems to impart antifouling properties and prolong the in vivo circulation time.56-59 Another good example of clinically approved synthetic polymers is PLGA, which is widely recognized for its excellent biodegradability and biocompatibility and extensively studied as drug delivery vehicles.60-63 Overall, the synthetic organic building blocks could be an important instrument in a broad array of cancer-related applications including drug delivery and bioimaging. With the rapid advances in tumor pathology and our understanding of the interaction at molecular and nanoscale level, some natural biomacromolecules are increasingly being used for the fabrication of self-assembly-based nanoscale constructs, which may bring potential benefit to cancer patients. Notably, these emerging natural or naturally derived organic building blocks include and not limited to proteins,64-66 peptides/polypeptides,67-70 DNA,71-74 polysaccharides.75,

76

Several new preparation methods have also been developed for the

nanofabrication by the self-assembly of these substrates. For instances, one of the major breakthroughs in DNA bioengineering technology is the DNA origami, which uses multiple short complementary oligonucleotides to fold a long strand of DNA into a predetermined shape.77 The programmable flexibility of DNA origami enables the preparation of welldefined multidimensional biofunctional materials.78, 79 More importantly, recent insights have demonstrated that biomolecules and nanoparticle species could also be incorporated into DNA origami structures, which further expand their application potential.80 Another example is the self-assembly of polyelectrolytes,81,

82

which could be used to produce supramolecular

nanomaterials with tailorable structures and versatile functions using charged or chargeable biomacromolecules including polypeptides, glycosaminoglycans and DNA.83,

84

Compared

with their synthetic counterparts, these natural or naturally derived organic building blocks may provide unique advantages for many cancer-related pharmaceutical applications, as many of them are intrinsically bioactive. However, it is also worth noting that despite their biological origin, extensive testing and characterization are still needed to thoroughly evaluate their in vivo efficacy and safety.

4. Inorganic nanomaterials for cancer diagnostics and therapy

In the earliest times, a lot of scientific effort for pharmaceutical nanotechnology has been devoted to the development of “soft” nanoplatforms based on organic constructions units, which possess excellent biocompatibility and versatile surface chemistry. However, with the improved understanding of inorganic chemistry and molecular biology, inorganic nanomaterials with irreplaceable physio-chemical 10 Environment ACS Paragon Plus

Page 11 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


properties have also attracted increasing interest for biomedical applications. Compared with their organic counterparts, inorganic nanoparticles have many unique and interesting functionalities, such as the high luminescence of quantum dots (QDs),85 superparamagnetic behavior of iron oxide nanoparticles86,

87

and localized surface

plasmon resonance of gold nanorods.88 These physicochemical functionalities are highly desired for biomedical applications like high-resolution in vivo imaging or photothermal ablation, but are rarely found on those organic materials currently available. However, the clinical translation of these inorganic nanoparticles has been initially impeded by many intrinsic and persistent issues. It has been consistently revealed in many reports that using unmodified inorganic nanoparticles for clinical applications could raise potential health risks due to their problematic bioaccumulation, biodegradability, difficult body clearance, etc. Additionally, much of the physiological detail regarding the pharmacokinetic characteristics and biological impacts of these inorganic-nanoparticle-based nanomedicine, such as their body distribution, circulation time, disease-targeting efficiency and immune response, still remains to be elucidated, which may further hamper their clinical translation.89-95 After years of development, there are already many approaches for the biofunctionalization of inorganic substrates. Some of the most frequently used methods are (1) conjugating biomacromolecules onto inorganic nanoparticles with covalent linkage or (2) coating the particle surface with biocompatible synthetic materials such as functional polymers and mesoporous silica.96 Overall, these methods are wellproven modification strategies, which may significantly improve the bioavailability and biocompatibility of the inorganic components. Nevertheless, it usually requires a series of complex chemical reactions to achieve high-affinity binding of the bioactive moieties, which may have potential negative impact on their biofunctionality. As technologies advance, alternative preparation methods for organic-inorganic hybrid materials are urgently needed, which should be safe, fast, simple and versatile. Table 3 presents some representative inorganic nanosystems that have been approved or under clinical trials.97-105

Table 3. Representative nanosystems with FDA-approval or under clinical trials that contain inorganic components. Marketed nanosystems comprising biofunctional inorganic components Trade name

Company

Composition

Indication


Year approved

Ref.


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Nanotherm®

MagForce

Feridex®/End

AMAG

orem®

pharmaceuticals

GastroMARK

AMAG

TM

/umirem®

pharmaceuticals

Iron oxide nanoparticles

Page 12 of 64

Hyperthermia ablation of glioblastoma

Dextran coated SPION

In vivo imaging

Silicone coated SPION

In vivo imaging

2010

FDA (1996)

97

98

Discontinued (2008)

2009

99

Inorganic nanosystems currently under clinical trials Name

Sponsor

Composition

Advantage Can be irritated by

AuroLase

Nanospectra

PEGylated silica-

Biosciences

gold nanoshells

near infrared light for thermal ablation

Indication

Thermal ablation of solid primary and/or metastatic lung tumors

ClinicalTrials.gov identifier (phase)

NCT01679470

Ref.

100

(Not provided)

Can enhance NBTXR3/PEP 503

Nanobiotix

Hafnium oxide nanoparticles

tumor cell death

Locally advanced

via electron

squamous cell

production under

carcinoma

NCT01946867 (I)

101

external radiation Silica nanoparticles with an NIR

Cornell Dots

Hybrid Silica Technologies

fluorophore, PEG coating, and a 124I radioable-led

Brighter fluoresce than existing dyes

Imaging of malignant brain tumors and melanoma

NCT01266096

102

(Not provided)

cRGDY targeting peptide Circumvent the Magnablate

University College London

Iron nanoparticles

long-term risks of

Thermal ablation for

surgical prostate

prostate cancer

NCT02033447 (0)

103

removal Sienna+®/Sent iMag®

TNF-Bound Colloidal Gold

Iron oxide particles Endomagnetics

coated with carboxydextran

National Institutes

Colloidal gold-

of Health Clinical

bound tumor

Center

necrosis factor

High accuracy and reliability

Mark and locate cancerous lymph nodes prior to surgery

Lowered cost with

Stimulate the immune

comparable

system and stop tumor

efficiency

cells from growing

NCT01790399;

104

NCT02249208

NCT00356980

105

(Not provided)

5. Self-assembled organic-inorganic hybridized nanobiomaterials: principles and supramolecular assembly strategies

Self-assembly techniques are emerging as an important approach for the nanoengineering of organic/inorganic hybrid nanosystems. Compared with those previously mentioned conventional functionalization strategies, the self-assembly approach excels with their excellent generality, simple preparation, low cost and versatile combination of functional components. With rationally designed components and aggregation mechanisms, the self-assembly technologies could not only effectively improve the 12 Environment ACS Paragon Plus

Page 13 of 64

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


biocompatibility of inorganic nanoparticles, but also facilitate the engineering of specialized types of hybrid materials that are tailored to specific clinical needs. Particularly, the self-assembly approach could retain and improve the unique properties of inorganic nanoparticles, as well as to endow them with new powers through modification and supramolecular interaction. For instance, it is now widely acknowledged by the biomedical scientific community that due to their unfavorable size, charge and chemical composition, most inorganic nanoparticles have difficulties to be efficiently removed from the body as intact nanoparticles or degraded into biologically benign compounds, thus greatly amplifying their potential long-term toxicity.106-108 In this regard, the self-assembly approach provides alternative avenues for the engineering of inorganic nanoparticles and incorporation of chemotherapeutics, which are functionally balanced between long blood circulation/sustained treatment and rapid clearance of the depleted nanocarriers from the body. In summary, such advantages are critical for the development of advanced inorganic nanoparticle based pharmaceutical nanosystems, and may further promote their clinical translation. A plethora of techniques have been developed to integrate heterogeneous components into biofunctional nanostructures via self-assembly, most of which belong to the so-called “bottom-up” approach. Though some factors or parameters may vary depending on situations, these preparation methods all rely on the utilization of supramolecular chemistry and non-covalent physiochemical forces to achieve the spontaneous formation of the proposed nanostructures. Based on how the building blocks were organized and controlled, as well as considering the popularity in biomedical research and the impact on industrial production, the existing self-assembly strategies could be roughly divided into co-assembly, hierarchical self-assembly and directed self-assembly, which will be introduced briefly below.109 Co-assembly. The co-assembly technique refers to the simultaneously self-assembly of multiple different building blocks into a synergic nanosystem. The basic concepts have been excellently demonstrated in the study by Guo et al, in which they reported a facile co-assembly method to prepare various heterogeneous superstructures using polyphenol as the functional ligand to mediate the interlocking process. Moreover, the functionalization and assembly of the components are simple and modular, which could be used for the rapid production of assemblies over a wide range of length scale.110



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Hierarchical self-assembly. The defining feature of hierarchical self-assembly is that the self-assembly process could be temporally divided into multiple stages. Typically, the basic molecular building blocks will first organize into a “first-order” assembly, which would be used as the building block to afford a “second-order” assembly. Such process could be repeated for many times, eventually leading to a supramolecular nanostructure of increasing size and complexity.111-113 Using this strategy, scientists were able to create various biofunctional superstructures out of simple structural units. For instance, Mout et al fabricated highly sophisticated multilayered hybrid nanostructure with recombinant proteins and engineered gold nanoparticles, in which the individual protein molecules and nanoparticles first co-assembled into discrete colloids (size: ~10 nm) and then aggregate into a granule-like structure (size:

Self-Assembled Hybrid Nanostructures: Versatile Multifunctional

Recommend Documents